{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T06:28:37Z","timestamp":1789972117147,"version":"4.0.1"},"reference-count":45,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bone"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1016\/j.bone.2011.02.003","type":"journal-article","created":{"date-parts":[[2011,2,12]],"date-time":"2011-02-12T11:25:26Z","timestamp":1297509926000},"page":"71-76","source":"Crossref","is-referenced-by-count":155,"title":["Bisphosphonates in oncology"],"prefix":"10.1016","volume":"49","author":[{"given":"Robert E.","family":"Coleman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene V.","family":"McCloskey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"20 Pt 2","key":"10.1016\/j.bone.2011.02.003_bb0005","doi-asserted-by":"crossref","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","article-title":"Clinical features of metastatic bone disease and risk of skeletal morbidity","volume":"12","author":"Coleman","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bone.2011.02.003_bb0010","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/jnci\/dji002","article-title":"Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors","volume":"97","author":"Brown","year":"2005","journal-title":"J. Natl Cancer Inst."},{"issue":"8","key":"10.1016\/j.bone.2011.02.003_bb0015","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1093\/annonc\/mdn164","article-title":"Practical guidance for the management of aromatase inhibitor-associated bone loss","volume":"19","author":"Hadji","year":"2008","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.bone.2011.02.003_bb0020","first-page":"CD002068","article-title":"Bisphosphonates for the relief of pain secondary to bone metastases","author":"Wong","year":"2002","journal-title":"Cochrane Database Syst Rev."},{"issue":"11","key":"10.1016\/j.bone.2011.02.003_bb0025","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/sj.bjc.6604382","article-title":"Risks and benefits of bisphosphonates","volume":"98","author":"Coleman","year":"2008","journal-title":"Br. J. Cancer"},{"issue":"11","key":"10.1016\/j.bone.2011.02.003_bb0030","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer","volume":"96","author":"Saad","year":"2004","journal-title":"J. Natl Cancer Inst."},{"issue":"12","key":"10.1016\/j.bone.2011.02.003_bb0035","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/cncr.20308","article-title":"Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial","volume":"100","author":"Rosen","year":"2004","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.bone.2011.02.003_bb0040","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/annonc\/mdm442","article-title":"Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel","volume":"19","author":"Aapro","year":"2008","journal-title":"Ann. Oncol."},{"issue":"8","key":"10.1016\/j.bone.2011.02.003_bb0045","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.bone.2011.02.003_bb0050","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1093\/annonc\/mdg367","article-title":"Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases","volume":"14","author":"Body","year":"2003","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.bone.2011.02.003_bb0055","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.pain.2004.07.011","article-title":"Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer","volume":"111","author":"Body","year":"2004","journal-title":"Pain"},{"issue":"15 Suppl.","key":"10.1016\/j.bone.2011.02.003_bb0060","doi-asserted-by":"crossref","first-page":"8021","DOI":"10.1200\/jco.2010.28.15_suppl.8021","article-title":"Evaluating the effects of zoledronic acid (ZOL) on overall survival (OS) in patients (Pts) with multiple myeloma (MM): results of the Medical Research Council (MRC) Myeloma IX study","volume":"28","author":"Morgan","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"22","key":"10.1016\/j.bone.2011.02.003_bb0065","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1200\/JCO.2005.06.091","article-title":"Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid","volume":"23","author":"Coleman","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bone.2011.02.003_bb0070","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/cncr.23529","article-title":"Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid","volume":"113","author":"Lipton","year":"2008","journal-title":"Cancer"},{"issue":"30","key":"10.1016\/j.bone.2011.02.003_bb0075","doi-asserted-by":"crossref","first-page":"4895","DOI":"10.1200\/JCO.2006.05.9212","article-title":"Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy","volume":"24","author":"Clemons","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.bone.2011.02.003_bb0080","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research","volume":"22","author":"Khosla","year":"2007","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2011.02.003_bb0085","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","author":"Stopeck","year":"2010","journal-title":"J Clin Oncol."},{"issue":"8","key":"10.1016\/j.bone.2011.02.003_bb0090","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nrc867","article-title":"Metastasis to bone: causes, consequences and therapeutic opportunities","volume":"2","author":"Mundy","year":"2002","journal-title":"Nat. Rev. Cancer"},{"issue":"9503","key":"10.1016\/j.bone.2011.02.003_bb0095","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1016\/S0140-6736(05)67887-7","article-title":"Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials","volume":"366","author":"Clarke","year":"2005","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1016\/j.bone.2011.02.003_bb0100","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1053\/j.seminoncol.2010.06.008","article-title":"Potential anticancer properties of bisphosphonates","volume":"37","author":"Neville-Webbe","year":"2010","journal-title":"Semin. Oncol."},{"issue":"5","key":"10.1016\/j.bone.2011.02.003_bb0105","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.ctrv.2008.02.004","article-title":"Exploring the anti-tumour activity of bisphosphonates in early breast cancer","volume":"34","author":"Winter","year":"2008","journal-title":"Cancer Treat. Rev."},{"issue":"11","key":"10.1016\/j.bone.2011.02.003_bb0110","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.2174\/138161210791034003","article-title":"Bisphosphonates as treatment of bone metastases","volume":"16","author":"Holen","year":"2010","journal-title":"Curr. Pharm. Design"},{"issue":"3","key":"10.1016\/j.bone.2011.02.003_bb0115","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/0959-8049(95)00564-1","article-title":"Does supportive pamidronate treatment prevent or delay the first manifestation of bone metastases in breast cancer patients?","volume":"32A","author":"van Holten-Verzantvoort","year":"1996","journal-title":"Eur. J. Cancer"},{"issue":"6","key":"10.1016\/j.bone.2011.02.003_bb0120","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S8756-3282(96)00285-2","article-title":"Clodronate decreases the frequency of skeletal metastases in women with breast cancer","volume":"19","author":"Kanis","year":"1996","journal-title":"Bone"},{"issue":"Suppl 1","key":"10.1016\/j.bone.2011.02.003_bb0125","first-page":"S53","article-title":"Treatment of skeletal disease in breast cancer: a controlled clodronate trial","volume":"8","author":"Elomaa","year":"1987","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.bone.2011.02.003_bb0130","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1200\/JCO.2001.19.1.10","article-title":"Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial","volume":"19","author":"Saarto","year":"2001","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.bone.2011.02.003_bb0135","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1056\/NEJM199808063390601","article-title":"Reduction in new metastases in breast cancer with adjuvant clodronate treatment","volume":"339","author":"Diel","year":"1998","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.bone.2011.02.003_bb0140","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1186\/bcr1384","article-title":"Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]","volume":"8","author":"Powles","year":"2006","journal-title":"Breast Cancer Res."},{"issue":"7","key":"10.1016\/j.bone.2011.02.003_bb0145","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1056\/NEJMoa0806285","article-title":"Endocrine therapy plus zoledronic acid in premenopausal breast cancer","volume":"360","author":"Gnant","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.bone.2011.02.003_bb0150","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1093\/annonc\/mdn429","article-title":"Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up","volume":"19","author":"Diel","year":"2008","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.bone.2011.02.003_bb0155","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.ejca.2009.12.003","article-title":"Effect of oral clodronate on bone mass, bone turnover and subsequent metastases in women with primary breast cancer","volume":"46","author":"McCloskey","year":"2010","journal-title":"Eur. J. Cancer"},{"issue":"13","key":"10.1016\/j.bone.2011.02.003_bb0160","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1158\/1078-0432.CCR-03-0325","article-title":"Zoledronic acid inhibits visceral metastases in the 4T1\/luc mouse breast cancer model","volume":"10","author":"Hiraga","year":"2004","journal-title":"Clin. Cancer Res."},{"issue":"16","key":"10.1016\/j.bone.2011.02.003_bb0165","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1093\/jnci\/djn240","article-title":"Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer","volume":"100","author":"Ottewell","year":"2008","journal-title":"J. Natl Cancer Inst."},{"issue":"14","key":"10.1016\/j.bone.2011.02.003_bb0170","doi-asserted-by":"crossref","first-page":"4658","DOI":"10.1158\/1078-0432.CCR-07-1545","article-title":"Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo","volume":"14","author":"Ottewell","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.bone.2011.02.003_bb0175","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ctrv.2005.01.008","article-title":"The causes and treatment of bone loss associated with carcinoma of the breast","volume":"31","author":"Lester","year":"2005","journal-title":"Cancer Treat. Rev."},{"issue":"Suppl 2","key":"10.1016\/j.bone.2011.02.003_bb0180","first-page":"9","article-title":"Bone health in men with prostate cancer: diagnostic and therapeutic considerations","volume":"12","author":"Saad","year":"2005","journal-title":"Can. J. Urol."},{"key":"10.1016\/j.bone.2011.02.003_bb0185","doi-asserted-by":"crossref","unstructured":"Geisler J, Lonning PE. Impact of aromatase inhibitors on bone health in breast cancer patients. J Steroid Biochem Mol Biol., Feb 28;118(4\u20135): 294\u20139.","DOI":"10.1016\/j.jsbmb.2009.10.004"},{"issue":"21","key":"10.1016\/j.bone.2011.02.003_bb0190","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.2003.08.017","article-title":"American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer","volume":"21","author":"Hillner","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 1","key":"10.1016\/j.bone.2011.02.003_bb0195","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.ctrv.2008.03.007","article-title":"Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group","volume":"34","author":"Reid","year":"2008","journal-title":"Cancer Treat. Rev."},{"issue":"5","key":"10.1016\/j.bone.2011.02.003_bb0200","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1634\/theoncologist.2007-0206","article-title":"Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole","volume":"13","author":"Brufsky","year":"2008","journal-title":"Oncologist"},{"key":"10.1016\/j.bone.2011.02.003_bb0205","doi-asserted-by":"crossref","unstructured":"Van Poznak C. Managing bone mineral density with oral bisphosphonate therapy in women with breast cancer receiving adjuvant aromatase inhibition. Breast Cancer Res. 12(3):110.","DOI":"10.1186\/bcr2584"},{"issue":"19","key":"10.1016\/j.bone.2011.02.003_bb0210","doi-asserted-by":"crossref","first-page":"6336","DOI":"10.1158\/1078-0432.CCR-07-5101","article-title":"Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer","volume":"14","author":"Lester","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.bone.2011.02.003_bb0215","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1200\/JCO.2006.07.3361","article-title":"Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer","volume":"25","author":"Michaelson","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.bone.2011.02.003_bb0220","doi-asserted-by":"crossref","first-page":"416","DOI":"10.7326\/0003-4819-146-6-200703200-00006","article-title":"Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial","volume":"146","author":"Greenspan","year":"2007","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.bone.2011.02.003_bb0225","series-title":"Handbook of cancer-related bone disease: Bioscientifica","article-title":"Assessment of bone health","author":"McCloskey","year":"2010"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S875632821100055X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S875632821100055X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,8]],"date-time":"2019-06-08T14:29:41Z","timestamp":1560004181000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S875632821100055X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["S875632821100055X"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2011.02.003","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2011,7]]}}}